Join
Live feed
·
PRReleasevia Quantisnow
Larimar Therapeutics Inc. logo

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

ByQuantisnow·Wall Street's wire, on your screen.
LRMR· Larimar Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LRMR (Larimar Therapeutics Inc.) and more on Quantisnow.